This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
Eculizumab - Indications, Dosage, Side Effects and Precautions
300 mg/30mL, Injection, solution, concentrate
INN: ECULIZUMAB
Data updated: 2026-04-26
Available in:
🇬🇧🇵🇹
Form
INJECTION, SOLUTION, CONCENTRATE
Dosage
300 mg/30mL
Route
INTRAVENOUS
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Amgen Inc
ATC Code
L04AJ01
Source
OPENFDA_NDC
Eculizumab is a monoclonal antibody, which is prescribed for two conditions:
• Paroxysmal nocturnal hemoglobinuria (PNH) in which red blood cells (RBCs) are broken down resulting in anemia and decreased oxygen supply to the body.
• Atypical hemolytic uremic syndrome (aHUS), where small blood clots are formed which block blood supply and cause damage to kidney and other organs.
Eculizumab is an orphan drug since it is used only for the above rare conditions. It acts by blocking a part of the immune system called the complement system. In paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, the complement system acts abnormally and destroys the red blood cells and increases the risk of blood clots respectively.
⚠️ Warnings
•Caution should be exercised in patients with history of infection, fever, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.
Avoid contact with people who have infections.
Immunize patients with meningococcal vaccine two weeks prior to the treatment, as eculizumab increases the risk of life-threatening and fatal meningococcal infections. Children should also be vaccinated against Streptococcus pneumoniae and Hemophilus influenza type b (Hib).
• Because of the risk of meningococcal infections, eculizumab is made available only to prescribers who enroll in Risk Evaluation and Mitigation Strategy (REMS) program. The physician should educate the patient about the risk of meningococcal infection following use of the drug. The patient should be followed up and carry a card indicating his/her risk for meningococcal infection till about three months following the completion of treatment.
Inform your doctor about the use of other medications before the administration of eculizumab to avoid serious side effects.